Literature DB >> 12712428

Disease-drug interaction: Reduced response to propranolol despite increased concentration in the rat with inflammation.

Micheal S Guirguis1, Fakhreddin Jamali.   

Abstract

Inflammatory conditions reduce clearance, hence increase plasma concentration of drugs such as propranolol that are efficiently cleared by the liver. The therapeutic consequences of this increased plasma drug concentration is mainly unknown. However, for sotalol, another beta-adrenergic antagonist, inflammation causes reduced potency. Sotalol, however, is renally cleared; hence, its clearance is unaffected by inflammation. We examined if the inflammation-induced increased plasma propranolol concentration compensates for the reduced responsiveness. A modified lead I ECG was used to record PR interval and heart rate (HR). ECG was monitored following oral administration of 3, 5, 10, 15, 20, 25, and 30 mg/kg propranolol to both control and adjuvant arthritis (AA) rats. To confirm altered pharmacokinetics, single 25 mg/kg doses of propranolol were administered to both AA and control rats, with an inserted cannula in their right jugular vein for serial blood sampling. As expected, AA caused a significant reduction in the propranolol oral clearance and subsequently substantial increases in plasma total and unbound drug concentration. Interestingly, however, despite the elevated propranolol concentrations, the effect on HR remained unchanged and the prolongation of PR interval was significantly reduced in AA compared with control rats. The reduced sensitivity to propranolol in AA rats is suggestive of altered beta-adrenergic receptors function. Copyright 2003 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 92:1077-1084, 2003

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12712428     DOI: 10.1002/jps.10381

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Adjuvant arthritis-induced changes on ampicillin binding in serum and tissues under the influence of non-steroidal anti-inflammatory drugs in rats.

Authors:  E Tigka; I Daskala; G Rallis; S Anagnostopoulou; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Oct-Dec       Impact factor: 2.441

2.  Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.

Authors:  Forough Sanaee; John D Clements; Alistair W G Waugh; Richard N Fedorak; Richard Lewanczuk; Fakhreddin Jamali
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

3.  Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis.

Authors:  Waheed Asghar; Ali Aghazadeh-Habashi; Fakhreddin Jamali
Journal:  Inflammopharmacology       Date:  2017-04-07       Impact factor: 4.473

Review 4.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

5.  Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers.

Authors:  S Hanafy; N J Dagenais; W F Dryden; F Jamali
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

6.  In vitro Dissolution Studies on Solid Dispersions of Mefenamic Acid.

Authors:  K R S Sambasiva Rao; M V Nagabhushanam; K P R Chowdary
Journal:  Indian J Pharm Sci       Date:  2011-03       Impact factor: 0.975

Review 7.  The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders.

Authors:  Kuo-Chen Wu; Chun-Jung Lin
Journal:  J Food Drug Anal       Date:  2018-12-04       Impact factor: 6.157

Review 8.  Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.

Authors:  Françoise Stanke-Labesque; Elodie Gautier-Veyret; Stephanie Chhun; Romain Guilhaumou
Journal:  Pharmacol Ther       Date:  2020-07-11       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.